tamoxifen,Exemestane,Triptorelin
Astrazeneca,Pfizer,Azurity Pharmaceuticals
['bcsm', 'ovarian', 'core i']
pam50 intrinsic subtype and ror score in her2- premenopausal women in soft in women &lt;40 yo: more high ror, more luminal b and non-luminal subtypes ror prognostic in premenopausal women. ror not predictive of ovarian suppression benefit. lauren brown #bcsm #asco23 
Medical oncologist @Intermountain, Director of Breast Oncology. Clinical research, quality improvement, cardio-oncology, provider wellness. All tweets my own.